Dopamine supersensitivity psychosis

Last updated

Dopamine supersensitivity psychosis is a hypothesis that attempts to explain the phenomenon in which psychosis (e.g., hallucinations, delusions) occurs despite treatment with escalating doses of antipsychotics. [1] Dopamine supersensitivity may be caused by the dopamine receptor D2 antagonizing effect of antipsychotics, causing a compensatory increase in D2 receptors within the brain that sensitizes neurons to endogenous release of the neurotransmitter dopamine. Because psychosis is thought to be mediated—at least in part—by the activity of dopamine at D2 receptors, the activity of dopamine in the presence of supersensitivity may paradoxically give rise to worsening psychotic symptoms despite antipsychotic treatment at a given dose. This phenomenon may co-occur with tardive dyskinesia, a rare movement disorder that may also be due to dopamine supersensitivity.

Contents

Mechanism

Dopamine supersensitivity psychosis may occur due to upregulation of dopamine D2 receptors. The D2 receptor is the primary target of almost all antipsychotics, which oppose the action of the neurotransmitter dopamine at this receptor. The antagonizing of D2 receptors by antipsychotics may cause neurons to undergo compensatory changes to make up for the loss of activity at D2 receptors. The D2 signaling pathway within neurons is complex and involves multiple enzymes and other secondary messengers. It may be the case that, in response to antipsychotics, neurons increase the production of D2 receptors (upregulation), thereby sensitizing the neuron to dopamine. [2] However, this is likely an oversimplification, as—despite differences in sensitivity to dopamine of around 3-fold in people that have taken antipsychotics chronically—there is a disproportionately low increase in the amount of D2 receptors in the brain in these people (around 1.4-fold in the striatum of the brain in people with schizophrenia). [3] Other hypotheses include increases in the "active" D2 receptors (termed D2High) relative to the "inactive" conformation (D2Low). [3]

The result is dopamine supersensitivity. It is thought that the psychotic symptoms within schizophrenia are primarily due to overactive dopamine activity in the mesolimbic area of the brain. [4] Therefore, dopamine supersensitivity may reduce the effect of antipsychotics and increase the brain's response to endogenous dopamine, leading to worsening psychosis. [4]

Tardive dyskinesia, a type of rare movement disorder that can be caused by antipsychotics, may also be caused by dopamine receptor sensitization. This may explain why, for people with tardive dyskinesia, increasing the dose of the antipsychotic may temporarily improve symptoms. [5] The theory of dopamine supersensivity may also explain some occurrences of tardive dyskinesia called withdrawal-emergent dyskinesia, when antipsychotic medication is abruptly discontinued. [6]

Diagnosis

The original criteria for dopamine supersensitivity psychosis were the following: [1]

  • 1. Rebound psychosis within 6 weeks of a change (e.g. dose reduction, or antipsychotic switching) in an oral antipsychotic regimen or 3 months for long-acting injectable antipsychotics
  • 2. Tolerance to antipsychotic effects (requiring escalating doses, even beyond what has controlled symptoms in the past)
  • 3. Presence of tardive dyskinesia (which should occur when antipsychotics are withdrawn, and improve or disappear when antipsychotics are restarted)

Differential diagnosis

It may sometimes be impossible to distinguish dopamine supersensitivity psychosis from psychosis that occurs "naturally" in the course of a primary psychotic disorder like schizophrenia, including cases in which the person was not taking their antipsychotic medication. [1] Even in the presence of an alternative etiology, or when it is impossible to determine the precise etiology for a psychotic episode, it is possible that dopamine supersensitivity psychosis can play a role in the presentation. [1] Recognizing the possible role of dopamine supersensitivity psychosis in a psychotic episode has implications for how to best manage someone's antipsychotic therapy. [1]

History

When supersensitivity psychosis was explored in 1978, [7] a featured concern was increasing resistance to medication, requiring higher doses or not responding to higher doses. Some articles use the term tardive psychosis to reference to this specific concept. [8] However, articles have disputed its validity. [8] [9] The condition has been discovered in very few people. [8] [10] Palmstierna asserts that tardive psychosis is a combination of "several different and not necessarily correlated phenomena related to neuroleptic treatment of schizophrenia." [8]

Society and culture

Dopamine supersensitivity is often dismissed as an inconsequential factor in the progression of psychotic disorders by psychiatrists in the medical literature. [2] The dopamine supersensitivity hypothesis was discussed by investigative journalist and author Robert Whitaker in his book Anatomy of an Epidemic , published in 2010. [a]

Research

As of 2017, much of the evidence for dopamine supersensitivity psychosis comes from studies performed in animals. There is still a need for robust, human research. [2]

In a cohort study of people taking chronic antipsychotic therapy with either schizophrenia or schizoaffective disorder that presented for psychiatric care due to a relapse of their psychotic symptoms without a clear precipitating cause (e.g. new or worsening substance abuse, evidence of nonadherence to antipsychotics), 39% of the sample met the authors' checklist for dopamine supersensitivity psychosis. The people that met the criteria were more likely than others to have worse symptoms when their psychosis returned (relapsed), have residual psychotic symptoms, had overall worse health outcomes at 6-month follow-ups, and were more likely to live in residential care. [15]

Further reading

Notes

  1. ↑ Whitaker's book, a New York Times bestseller, discusses the work of Chouinard and Jones in the section "Supersensitivity Psychosis". Whitaker comments that "In the late 1970s, two physicians at McGill University, Guy Chouinard and Barry Jones, stepped forward with a biological explanation for why the drugs made schizophrenia patients more biologically vulnerable to psychosis". Paraphrasing their work he says: "The severe relapse suffered by many patients withdrawn from antipsychotics was not necessarily the result of the "disease" returning, but rather was drug-related", and "In short, initial exposure to neuroleptics put patients onto a path where they would likely need the drugs for life." [11] This book was reviewed in Time , [12] Scientific American , [13] and the New York Review of Books . [14]

Related Research Articles

<span class="mw-page-title-main">Antipsychotic</span> Class of medications

Antipsychotics, previously known as neuroleptics and major tranquilizers, are a class of psychotropic medication primarily used to manage psychosis, principally in schizophrenia but also in a range of other psychotic disorders. They are also the mainstay, together with mood stabilizers, in the treatment of bipolar disorder. Moreover, they are also used as adjuncts in the treatment of treatment-resistant major depressive disorder.

<span class="mw-page-title-main">Chlorpromazine</span> Antipsychotic medication

Chlorpromazine (CPZ), marketed under the brand names Thorazine and Largactil among others, is an antipsychotic medication. It is primarily used to treat psychotic disorders such as schizophrenia. Other uses include the treatment of bipolar disorder, severe behavioral problems in children including those with attention deficit hyperactivity disorder, nausea and vomiting, anxiety before surgery, and hiccups that do not improve following other measures. It can be given orally, by intramuscular injection, or intravenously.

<span class="mw-page-title-main">Haloperidol</span> Typical antipsychotic medication

Haloperidol, sold under the brand name Haldol among others, is a typical antipsychotic medication. Haloperidol is used in the treatment of schizophrenia, tics in Tourette syndrome, mania in bipolar disorder, delirium, agitation, acute psychosis, and hallucinations from alcohol withdrawal. It may be used by mouth or injection into a muscle or a vein. Haloperidol typically works within 30 to 60 minutes. A long-acting formulation may be used as an injection every four weeks for people with schizophrenia or related illnesses, who either forget or refuse to take the medication by mouth.

<span class="mw-page-title-main">Fluphenazine</span> Typical antipsychotic medication

Fluphenazine, sold under the brand name Prolixin among others, is a high-potency typical antipsychotic medication. It is used in the treatment of chronic psychoses such as schizophrenia, and appears to be about equal in effectiveness to low-potency antipsychotics like chlorpromazine. It is given by mouth, injection into a muscle, or just under the skin. There is also a long acting injectable version that may last for up to four weeks. Fluphenazine decanoate, the depot injection form of fluphenazine, should not be used by people with severe depression.

<span class="mw-page-title-main">Typical antipsychotic</span> Class of drugs

Typical antipsychotics are a class of antipsychotic drugs first developed in the 1950s and used to treat psychosis. Typical antipsychotics may also be used for the treatment of acute mania, agitation, and other conditions. The first typical antipsychotics to come into medical use were the phenothiazines, namely chlorpromazine which was discovered serendipitously. Another prominent grouping of antipsychotics are the butyrophenones, an example of which is haloperidol. The newer, second-generation antipsychotics, also known as atypical antipsychotics, have largely supplanted the use of typical antipsychotics as first-line agents due to the higher risk of movement disorders with typical antipsychotics.

<span class="mw-page-title-main">Atypical antipsychotic</span> Class of pharmaceutical drugs

The atypical antipsychotics (AAP), also known as second generation antipsychotics (SGAs) and serotonin–dopamine antagonists (SDAs), are a group of antipsychotic drugs largely introduced after the 1970s and used to treat psychiatric conditions. Some atypical antipsychotics have received regulatory approval for schizophrenia, bipolar disorder, irritability in autism, and as an adjunct in major depressive disorder.

<span class="mw-page-title-main">Perphenazine</span> Antipsychotic medication

Perphenazine is a typical antipsychotic drug. Chemically, it is classified as a piperazinyl phenothiazine. Originally marketed in the United States as Trilafon, it has been in clinical use for decades.

<span class="mw-page-title-main">Tardive dyskinesia</span> Neurological disorder featuring involuntary, repetitive body movements

Tardive dyskinesia (TD) is an iatrogenic disorder that results in involuntary repetitive body movements, which may include grimacing, sticking out the tongue or smacking the lips, which occurs following treatment with medication. Additional motor symptoms include chorea or athetosis. In about 20% of people with TD, the disorder interferes with daily functioning. If TD is present in the setting of a long-term drug therapy, reversibility can be determined primarily by severity of symptoms and how long symptoms have been present before the long-term drug has been stopped.

The dopamine hypothesis of schizophrenia or the dopamine hypothesis of psychosis is a model that attributes the positive symptoms of schizophrenia to a disturbed and hyperactive dopaminergic signal transduction. The model draws evidence from the observation that a large number of antipsychotics have dopamine-receptor antagonistic effects. The theory, however, does not posit dopamine overabundance as a complete explanation for schizophrenia. Rather, the overactivation of D2 receptors, specifically, is one effect of the global chemical synaptic dysregulation observed in this disorder.

<span class="mw-page-title-main">Dopamine antagonist</span> Drug which blocks dopamine receptors

A dopamine antagonist, also known as an anti-dopaminergic and a dopamine receptor antagonist (DRA), is a type of drug which blocks dopamine receptors by receptor antagonism. Most antipsychotics are dopamine antagonists, and as such they have found use in treating schizophrenia, bipolar disorder, and stimulant psychosis. Several other dopamine antagonists are antiemetics used in the treatment of nausea and vomiting.

<span class="mw-page-title-main">Prochlorperazine</span> Medication for nausea, psychosis, and anxiety

Prochlorperazine, formerly sold under the brand name Compazine among others, is a medication used to treat nausea, migraines, schizophrenia, psychosis and anxiety. It is a less preferred medication for anxiety. It may be taken by mouth, rectally, injection into a vein, or injection into a muscle.

<span class="mw-page-title-main">Amisulpride</span> Atypical antipsychotic and antiemetic medication

Amisulpride, sold under the brand names Solian and Barhemsys, is a medication used in the treatment of schizophrenia, acute psychotic episodes, depression, and nausea and vomiting. It is specifically used at lower doses intravenously to prevent and treat postoperative nausea and vomiting; at low doses by mouth to treat depression; and at higher doses by mouth to treat psychosis.

<span class="mw-page-title-main">Flupentixol</span> Typical antipsychotic drug of the thioxanthene class

Flupentixol (INN), also known as flupenthixol, marketed under brand names such as Depixol and Fluanxol is a typical antipsychotic drug of the thioxanthene class. It was introduced in 1965 by Lundbeck. In addition to single drug preparations, it is also available as flupentixol/melitracen—a combination product containing both melitracen and flupentixol . Flupentixol is not approved for use in the United States. It is, however, approved for use in the UK, Australia, Canada, Russian Federation, South Africa, New Zealand, Philippines, Iran, Germany, and various other countries.

Extrapyramidal symptoms (EPS) are symptoms that are archetypically associated with the extrapyramidal system of the brain's cerebral cortex. When such symptoms are caused by medications or other drugs, they are also known as extrapyramidal side effects (EPSE). The symptoms can be acute (short-term) or chronic (long-term). They include movement dysfunction such as dystonia, akathisia, parkinsonism characteristic symptoms such as rigidity, bradykinesia, tremor, and tardive dyskinesia. Extrapyramidal symptoms are a reason why subjects drop out of clinical trials of antipsychotics; of the 213 (14.6%) subjects that dropped out of one of the largest clinical trials of antipsychotics, 58 (27.2%) of those discontinuations were due to EPS.

<span class="mw-page-title-main">Iloperidone</span> Atypical antipsychotic medication

Iloperidone, commonly known as Fanapt and previously known as Zomaril, is an atypical antipsychotic for the treatment of schizophrenia and bipolar I disorder.

<span class="mw-page-title-main">Zuclopenthixol</span> Typical antipsychotic medication

Zuclopenthixol, also known as zuclopentixol, is a medication used to treat schizophrenia and other psychoses. It is classed, pharmacologically, as a typical antipsychotic. Chemically it is a thioxanthene. It is the cis-isomer of clopenthixol. Clopenthixol was introduced in 1961, while zuclopenthixol was introduced in 1978.

<span class="mw-page-title-main">Perospirone</span> Atypical antipsychotic medication

Perospirone (Lullan) is an atypical antipsychotic of the azapirone family. It was introduced in Japan by Dainippon Sumitomo Pharma in 2001 for the treatment of schizophrenia and acute cases of bipolar mania.

Tardive psychosis is a hypothetical form of psychosis caused by long-term use of neuroleptics. It was first proposed in 1978 but was questioned by the late 1980s. It was hypothesized that psychosis could arise as neuroleptic medication become decreasingly effective, requiring higher doses, or when not responding to higher doses.

<span class="mw-page-title-main">Aripiprazole lauroxil</span> Chemical compound

Aripiprazole lauroxil, sold under the brand name Aristada, is a long-acting injectable atypical antipsychotic that was developed by Alkermes. It is an N-acyloxymethyl prodrug of aripiprazole that is administered via intramuscular injection once every four to eight weeks for the treatment of schizophrenia. Aripiprazole lauroxil was approved by the U.S. Food and Drug Administration (FDA) on 5 October 2015.

<span class="mw-page-title-main">Antipsychotic switching</span> Process of transferring between antipsychotics

Antipsychotic switching refers to the process of switching out one antipsychotic for another antipsychotic. There are multiple indications for switching antipsychotics, including inadequate efficacy and drug intolerance. There are several strategies that have been theorized for antipsychotic switching, based upon the timing of discontinuation and tapering of the original antipsychotic and the timing of initiation and titration of the new antipsychotic. Major adverse effects from antipsychotic switching may include supersensitivity syndromes, withdrawal, and rebound syndromes.

References

  1. 1 2 3 4 5 Nakata, Y; Kanahara, N; Iyo, M (December 2017). "Dopamine supersensitivity psychosis in schizophrenia: Concepts and implications in clinical practice". Journal of Psychopharmacology. 31 (12): 1511–1518. doi:10.1177/0269881117728428. PMID   28925317. S2CID   1957881.
  2. 1 2 3 Yin, John; Barr, Alasdair; Ramos-Miguel, Alfredo; Procyshyn, Ric (14 December 2016). "Antipsychotic Induced Dopamine Supersensitivity Psychosis: A Comprehensive Review". Current Neuropharmacology. 15 (1): 174–183. doi:10.2174/1570159X14666160606093602. PMC   5327459 . PMID   27264948.
  3. 1 2 Seeman, Philip (April 2011). "All Roads to Schizophrenia Lead to Dopamine Supersensitivity and Elevated Dopamine D2High Receptors". CNS Neuroscience & Therapeutics. 17 (2): 118–132. doi:10.1111/j.1755-5949.2010.00162.x. PMC   6493870 . PMID   20560996.
  4. 1 2 Brisch, Ralf; Saniotis, Arthur; Wolf, Rainer; Bielau, Hendrik; Bernstein, Hans-Gert; Steiner, Johann; Bogerts, Bernhard; Braun, Anna Katharina; Jankowski, Zbigniew; Kumaritlake, Jaliya; Henneberg, Maciej; Gos, Tomasz (19 May 2014). "The Role of Dopamine in Schizophrenia from a Neurobiological and Evolutionary Perspective: Old Fashioned, but Still in Vogue". Frontiers in Psychiatry. 5: 47. doi: 10.3389/fpsyt.2014.00047 . PMC   4032934 . PMID   24904434.
  5. ↑ Katzung, BG; Kruidering-Hall, M; Trevor, AJ (eds.). "Chapter 29: Antipsychotic Agents & Lithium". Katzung & Trevor's Pharmacology: Examination & Board Review (12 ed.). McGraw-Hill.
  6. ↑ Karaş, Hakan; Güdük, Mehmet; Saatcioğlu, Ömer (June 2016). "Withdrawal-Emergent Dyskinesia and Supersensitivity Psychosis Due to Olanzapine Use". Noro Psikiyatri Arsivi. 53 (2): 178–180. doi:10.5152/npa.2015.10122 (inactive 2024-11-14). ISSN   1300-0667. PMC   5353025 . PMID   28360793.{{cite journal}}: CS1 maint: DOI inactive as of November 2024 (link)
  7. ↑ Chouinard G, Jones BD, Annable L (1978). "Neuroleptic-induced supersensitivity psychosis". Am J Psychiatry. 135 (11): 1409–10. doi:10.1176/ajp.135.11.1409. PMID   30291.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  8. 1 2 3 4 Palmstierna, T; Wistedt, B (1988). "Tardive psychosis: Does it exist?". Psychopharmacology. 94 (1): 144–5. doi:10.1007/BF00735897. PMID   2894699. S2CID   29048614.
  9. ↑ Kirkpatrick B, Alphs L, Buchanan RW (1992). "The concept of supersensitivity psychosis". J Nerv Ment Dis. 180 (4): 265–70. doi:10.1097/00005053-199204000-00009. PMID   1348269. S2CID   29597822.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  10. ↑ Chouinard G (1991). "Severe cases of neuroleptic-induced supersensitivity psychosis. Diagnostic criteria for the disorder and its treatment". Schizophr Res. 5 (1): 21–33. doi:10.1016/0920-9964(91)90050-2. PMID   1677263. S2CID   38211914.
  11. ↑ Whitaker, Robert (2015). Anatomy of an epidemic: magic bullets, psychiatric drugs, and the astonishing rise of mental illness in America (1st ed.). Crown Publishers. pp. 105–107. ISBN   9780307452429.
  12. ↑ Fitzpatrick, Laura (3 May 2010). "Book review: Anatomy of an Epidemic by Robert Whitaker". Time .
  13. ↑ "Are Psychiatric Medications Making Us Sicker?". Scientific American .
  14. ↑ Angell, Marcia. "The Epidemic of Mental Illness: Why?". New York Review of Books .
  15. ↑ Fallon, P; Dursun, S; Deakin, B (February 2012). "Drug-induced supersensitivity psychosis revisited: characteristics of relapse in treatment-compliant patients". Therapeutic Advances in Psychopharmacology. 2 (1): 13–22. doi: 10.1177/2045125311431105 . PMC   3736929 . PMID   23983951.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.